Context Therapeutics (CNTX) to Release Earnings on Thursday

Context Therapeutics (NASDAQ:CNTX) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

Context Therapeutics Price Performance

NASDAQ CNTX opened at $3.17 on Thursday. Context Therapeutics has a one year low of $0.49 and a one year high of $3.30. The business has a 50 day simple moving average of $2.15 and a 200 day simple moving average of $1.46. The stock has a market capitalization of $291.26 million, a P/E ratio of -13.21 and a beta of 1.96.

Institutional Investors Weigh In On Context Therapeutics

Several institutional investors have recently bought and sold shares of CNTX. Vanguard Group Inc. grew its stake in shares of Context Therapeutics by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after acquiring an additional 134,449 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Context Therapeutics during the 3rd quarter worth approximately $100,000. Renaissance Technologies LLC grew its holdings in shares of Context Therapeutics by 58.8% in the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after acquiring an additional 188,202 shares in the last quarter. State Street Corp grew its holdings in shares of Context Therapeutics by 8.5% in the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after acquiring an additional 13,000 shares in the last quarter. Finally, Marshall Wace LLP increased its position in shares of Context Therapeutics by 7,153.7% during the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after acquiring an additional 2,557,448 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CNTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. Lifesci Capital upgraded Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. Wall Street Zen downgraded Context Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Finally, JonesTrading started coverage on Context Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Context Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $6.00.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.